SCHEMBL1383613

SCHEMBL1383613

Oc1ccc(Cc2cnc(Nc3ccc(C(F)(F)F)c(C(F)(F)F)c3)c3ccccc23)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 8/20 0.40
▸ PDGFRB P09619 2/20 0.40
▸ KIT P10721 1/20 0.40
▸ FLT1 P17948 1/20 0.40
▸ NR1H2 P55055 3/20 0.36
▸ NR1H3 Q13133 3/20 0.36
▸ SYK P43405 1/20 0.35
▸ AURKB Q96GD4 2/20 0.35
▸ PPARG P37231 1/20 0.34
▸ PPARD Q03181 1/20 0.34
▸ PPARA Q07869 1/20 0.34
▸ EGFR P00533 1/20 0.33
▸ ABCG2 Q9UNQ0 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ AURKA O14965 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ NTRK1 P04629 1/20 0.33
▸ TYK2 P29597 1/20 0.33
▸ JAK3 P52333 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1386583 0.85 KDR (0.46) KDRPDGFRBKITFLT1NR1H2
SCHEMBL1386153 0.83 KDR (0.31) KDRPDGFRBKITFLT1EGFR
SCHEMBL1384909 0.82 KDR (0.50) KDRFLT1EGFRABCG2TSHR
SCHEMBL1385057 0.80 KDR (0.46) KDRPDGFRBKITFLT1SYK
SCHEMBL1387130 0.79 GAA (0.36) KDREGFRABCG2JAK3
SCHEMBL1386447 0.78 AURKA (0.37) KDREGFRABCG2AURKAJAK3
SCHEMBL1383504 0.75 KDR (0.44) KDRPDGFRBKITFLT1TSHR
SCHEMBL13955483 0.75 KDR (0.70) KDRPDGFRBKITFLT1AURKB
SCHEMBL4824553 0.74 KDM4E (0.48) KDREGFRABCG2TSHRHTT
SCHEMBL13955594 0.73 KDR (0.51) KDRPDGFRBKITFLT1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4837864-B2 — — 2011-12-14 — — JP claimed
US-7323474-B2 Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase NOVARTIS AG (CH) 2008-01-29 — — US claimed
EP-1254138-B1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE NOVARTIS AG (CH) 2005-05-11 — — EP claimed
US-20040209894-A1 Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase BOLD GUIDO 2004-10-21 — — US claimed
US-6706731-B2 WITH ISOQUINOLINE DERIVATIVES AS ANTITUMOR AGENTS NOVARTIS AG (CH) 2004-03-16 — — US claimed
US-20030158409-A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase NOVARTIS AG (CH) 2003-08-21 — — US claimed
EP-1254138-A1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE Novartis AG (CH) 2002-11-06 — — EP claimed
WO-2001058899-A1 PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE NOVARTIS AG (CH) 2001-08-16 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209894-A1 Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase FLT1, FLT4, KDR KDR 3/4885PDGFRB 10/4885KIT 21/4885
US-20030158409-A1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase FLT1, FLT4, KDR KDR 3/4885PDGFRB 7/4885KIT 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback